Priavoid started the first-in-human, first-in-class phase I-study of PRI-002 on April 16th 2018. A Phase II clinical trial is in preparation and scheduled to start in 2019.
Cookie Preference
Please select an option. You can find more information about the consequences of your choice at Help.
Select an option to continue
Your selection was saved!
Help
Help
To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.
You can change your cookie setting here anytime: Privacy Policy. Legal Notice
Back